Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q1 2024 · 10-Q
Revenue—
Net Income-$865.97K-$865.97KN/M vs Q1 2023 EPS Diluted-$1.31-$1.31N/M vs Q1 2023 Operating Income-$903,536N/M Operating Cash Flow-$1,303,411N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end